|Mr. Sébastien Peltier||Co-Founder, Chairman & CEO||N/A||N/A||1978|
|Mr. Jocelyn Pineau M.D.||Co-Founder, CFO & Director||N/A||N/A||N/A|
|Mr. Sebastien Bessy||Chief Operating Marketing & Bus. Officer and Director||N/A||N/A||N/A|
|Mr. Pascal Sirvent Ph.D.||CSO & Director||N/A||N/A||N/A|
|Ms. Murielle Cazaubiel||CMO & Director||N/A||N/A||N/A|
|Dr. Josep Infesta||Head of Global Bus. Devel.||N/A||N/A||N/A|
|Ms. Agnès Tixier||Exec. Director of Credit Mutuel & Equity SCR and Member of Supervisory Board||N/A||N/A||1969|
|Mr. Philippe Sibour||Chief Exec. Officer of Alliance Consulting||N/A||N/A||N/A|
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Valbiotis SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.